John Overington
Corporate Officer/Principal bij EXSCIENTIA PLC
Profiel
Dr. John P.
Overington is a Chief Data Officer at Exscientia Plc.
He is on the Board of Directors at The Cambridge Crystallographic Data Centre.
Dr. Overington was previously employed as a Senior Vice President-Drug Discovery by Galapagos Biotech Ltd., a Principal by Pfizer Central Research, and a Chief Information Officer by Medicines Discovery Catapult Ltd.
He received his doctorate degree from the University of London.
Actieve functies van John Overington
| Bedrijven | Functie | Begin |
|---|---|---|
| EXSCIENTIA PLC | Corporate Officer/Principal | 01-07-2021 |
The Cambridge Crystallographic Data Centre
 The Cambridge Crystallographic Data Centre Data Processing ServicesTechnology Services The Cambridge Crystallographic Data Centre, founded in 1965, is a non-profit company that specializes in providing support and licensing for their CSD data and software. The company is based in Cambridge, UK and has subsidiaries in the United Kingdom. The British company's historical structures date back to the 1920s. The CS-Crossminer software allows users to build pharmacophore queries and mine the CS data simultaneously. | Directeur/Bestuurslid | - |
Eerdere bekende functies van John Overington
| Bedrijven | Functie | Einde |
|---|---|---|
| Pfizer Central Research | Corporate Officer/Principal | - |
Medicines Discovery Catapult Ltd.
 Medicines Discovery Catapult Ltd. Miscellaneous Commercial ServicesCommercial Services Medicines Discovery Catapult Ltd. is a not-for-profit organization that enables the community to accelerate innovative drug discovery. The private company is based in Macclesfield, UK, and has subsidiaries in the United Kingdom. The British company focuses on pioneering the next generation of medicine discovery techniques and technologies by validating new ways of discovering medicines and driving key talent and expertise across the sector. The CEO of the company is Chris Molloy. | Hoofd Techniek/Wetenschap/O&O | - |
Galapagos Biotech Ltd.
 Galapagos Biotech Ltd. BiotechnologyHealth Technology Galapagos Biotech Ltd. operates as a drug discovery company which provides discovery technologies and services. Its technologies include Chemogenomics and Silico. The company was founded by Kenneth Leslie Powell and Janet Maureen Thornton in July 8, 1997 and is headquartered in Cambridge, the United Kingdom. | Corporate Officer/Principal | - |
Opleiding van John Overington
| University of London | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| EXSCIENTIA PLC | Health Technology |
| Bedrijven in privébezit | 4 |
|---|---|
Galapagos Biotech Ltd.
Galapagos Biotech Ltd. BiotechnologyHealth Technology Galapagos Biotech Ltd. operates as a drug discovery company which provides discovery technologies and services. Its technologies include Chemogenomics and Silico. The company was founded by Kenneth Leslie Powell and Janet Maureen Thornton in July 8, 1997 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
| Pfizer Central Research | |
The Cambridge Crystallographic Data Centre
The Cambridge Crystallographic Data Centre Data Processing ServicesTechnology Services The Cambridge Crystallographic Data Centre, founded in 1965, is a non-profit company that specializes in providing support and licensing for their CSD data and software. The company is based in Cambridge, UK and has subsidiaries in the United Kingdom. The British company's historical structures date back to the 1920s. The CS-Crossminer software allows users to build pharmacophore queries and mine the CS data simultaneously. | Technology Services |
Medicines Discovery Catapult Ltd.
Medicines Discovery Catapult Ltd. Miscellaneous Commercial ServicesCommercial Services Medicines Discovery Catapult Ltd. is a not-for-profit organization that enables the community to accelerate innovative drug discovery. The private company is based in Macclesfield, UK, and has subsidiaries in the United Kingdom. The British company focuses on pioneering the next generation of medicine discovery techniques and technologies by validating new ways of discovering medicines and driving key talent and expertise across the sector. The CEO of the company is Chris Molloy. | Commercial Services |
